1. Antiplatelet Therapy and Secondary Prevention

3. Learning Objectives

5. Data from PLATO, clopidogrel arm; primary efficacy endpoint = CV Death, MI, Stroke

6. REACH Registry CV Death/MI/stroke or Hospitalization for Atherothrombotic Events

7. Landmark Analyses Acute vs Chronic Trials

8. The Sweet Spot for Anticoagulation

9. Antiplatelet Therapy in ACS Management

11. Secondary Prevention in CAD Patients

12. Greater Efficacy of Ticagrelor or Prasugrel vs Clopidogrel

13. Clinical Benefit of Long-Term Antiplatelet Treatment

14. Patient #1 3 Months Post-MI

15. Patient #1: Evaluation at 6 Months Factors to Consider

16. On-going Risk Assessment Risk Categories

17. DAPT Trial 12 or 30 Months of Dual Antiplatelet Therapy

18. Patient #2 85-Year-Old, Frail, Woman

19. Vulnerable Patient vs Vulnerable Plaque Treatment Approaches

21. TRACER Vorapaxar for the Treatment of ACS (NSTEMI)

22. ADAPTABLE Low- vs Regular-strength Daily Dose of Aspirin in Patients With Known ASCVD

23. TWILIGHT Ticagrelor +/- Aspirin in High-Risk Patients After Coronary Intervention

24. GLOBAL LEADERS Ticagrelor vs Standard Dual Antiplatelet Therapy

25. Patient #3 On Dual Antiplatelet Therapy Needing Elective Procedure

26. Patient #4 Presenting With Recurrent NSTE ACS

27. PLATO Ticagrelor Efficacy in Patients Previously Treated With Clopidogrel

28. ACC/AHA Secondary Prevention Guidelines

29. Future Directions/Knowledge Gap

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)

34. References

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)